Introduction {#s1}
============

The World Health Organization (WHO) has compared hepatitis C to a \"viral time bomb\" and estimates that about 180 million people (some 3% of the world\'s population) are infected with hepatitis C virus (HCV), 130 million of whom are chronic carriers at risk of developing liver cirrhosis and/or liver cancer. Three to four million persons are newly infected each year, 70% of whom will develop chronic hepatitis. HCV is responsible for 50-76% of all liver cancer cases, and two thirds of all liver transplants in the developed world \[[@R1]\]. World Health Statistics 2008 lists cirrhosis of the liver as the 18th commonest cause of mortality in the world, and it is estimated that by 2030, liver cancer will become the 13th commonest cause \[[@R2]\].

The prevalence of hepatitis varies from country to country, and at times it will also vary among different regions of the same country. The epidemiological estimates by WHO show that the prevalence of hepatitis C is low (\< 1%) in Australia, Canada and northern Europe, and about 1% in countries of medium endemicity, such as the USA and most of Europe. It is high (\>2%) in many countries of Africa, Latin America, Central and South-East Asia. In these countries, prevalence figures between 5% and 10% are frequently reported \[[@R1]\].

Collecting and comparing health data from across a country is a way to describe health problems, identify trends and help decision-makers set priorities. The global epidemiology of hepatitis C is well established. However, its epidemiology in Pakistan is ill-defined. Most of the data have come from hospital-based studies, because there is a dearth of community-based ones \[[@R3]\]\[[@R4]\]\[[@R5]\]. Although the National Survey of Hepatitis has concluded, its results have not yet been officially published, except for a few presentations made by researchers at official meetings. This review summarizes the available data on the epidemiology of hepatitis C since the first report of its recognition in 1992.

HCV-Related Pakistani Data {#s2}
==========================

All available Pakistani data published or unpublished till the writing of this article were collected by a literature search through electronic databases like Pubmed, Pakmedinet, Yahoo and Google etc. Unpublished data from any source, if accessible, were also reviewed. Data from 132 published studies and 3 unpublished data sets were gathered and grouped in six categories, based on the type of population studied i.e. 1) general population, 2) blood donors, 3) patients with liver diseases, 4) patients with diseases other than hepatic diseases, 5) pregnant women and 6) children. Most of the data (78.5%) pertained to the years 2001-2008. Year by year distribution of this data is given in [Table 1](#s2tbl1){ref-type="table"}.

###### Distribution of studies and unpublished data sets by year of publication/data gathering/presentation.

  **Year**            **Number**   **Percent**
  ------------------- ------------ -------------
  2005 - 2008         47           34.8
  2001 - 2004         59           43.7
  1996 - 2000         20           14.8
  1995 and earlier.   9            6.7
  **Total**           **135**      **100.0**

General Population {#s3}
==================

Twenty-five studies \[[@R6]\]\[[@R7]\]\[[@R8]\]\[[@R9]\]\[[@R10]\]\[[@R11]\]\[[@R12]\]\[[@R13]\]\[[@R14]\]\[[@R15]\]\[[@R16]\]\[[@R17]\]\[[@R18]\]\[[@R19]\]\[[@R20]\]\[[@R21]\]\[[@R22]\]\[[@R23]\]\[[@R24]\]\[[@R25]\]\[[@R26]\]\[[@R27]\]\[[@R28]\]\[[@R29]\]\[[@R30]\] pertained to the serofrequency of hepatitis C in the general population. Details are given in [Table 2](#s3tbl2){ref-type="table"} The majority of these studies (92%) were conducted during the period 2000-2008. Two studies were conducted in the nineties \[[@R6]\]\[[@R7]\]. The data of 178,322 persons were included in this group. Unfortunately, there was no study from any major city of Balochistan, or from the NWFP provinces. The frequency of HCV infection ranged from 0.4% in Karachi \[[@R6]\] to 33.7% in Jarwar (Sindh) \[[@R28]\]. The mean frequency was 4.7% (95% confidence interval \[CI\]: 4.6 - 4.8).

###### Sero-Prevalence of HCV in General Population

  **Author**            **Year**    **Place**        **Number**    **Anti HCV (%)**                  **Reference**
  --------------------- ----------- ---------------- ------------- --------------------------------- ---------------
  Agboatwala *et al.*   1994        Karachi          258           0.4                               \[[@R6]\]
  Luby                  1997        Hafizabad        313           6.5                               \[[@R7]\]
  Aslam                 2001        Lahore           488           16.0                              \[[@R8]\]
  Aslam                 2001        Gujranwala       1,922         23.8                              \[[@R8]\]
  Ali *et al.*          2002        Rawalpindi       5,370         3.3                               \[[@R9]\]
  Khan                  2004        Mardan           700           9.0                               \[[@R10]\]
  Khokhar               2004        Islamabad        47,538        5.3                               \[[@R11]\]
  Muhammad              2005        Buner            16,400        4.6                               \[[@R12]\]
  Farooq *et al.*       2005        Khuzdar          665           3.3                               \[[@R13]\]
  Hashim *et al*        2005        Attock           4,552         4.0                               \[[@R14]\]
  Ahmad                 2006        Swat             41,613        2.2                               \[[@R15]\]
  Fayyaz *et al.*       2006        Bahawalpur       2,086         6.3                               \[[@R16]\]
  Tariq  and Janjua     2006        Rawalpindi       15,550        3.7                               \[[@R17]\]
  Jafri *et al.*        2006        Karachi          3,533         1.6                               \[[@R18]\]
  Sherif and Tariq      2006        Rawalpindi       2,558         2.8                               \[[@R19]\]
  Zaman                 2006        Bahawalpur       6,815         4.4                               \[[@R30]\]
  Ahmad *et al.*        2007        Faisalabad       300           16.0                              \[[@R20]\]
  Altaf *et al.*        2007        Hyderabad        2,835         5.2                               \[[@R21]\]
  Mirza *et al.*        2007        Bahawalpur       1821          2.5                               \[[@R22]\]
  Malik *et al.*        2008        Pannu Aqil       5,237         4.8                               \[[@R23]\]
  Hakim *et al.*        2007        Karachi          4,000         5.2                               \[[@R24]\]
  Buttand Amin          2008        DI Khan          5,707         1.7                               \[[@R25]\]
  Khan *et al.*         2008        Azad Kashmir     245           3.3                               \[[@R26]\]
  Idrees *et al.*       2008        Lahore           6,817         14.6                              \[[@R27]\]
  Abbas *et al.*        2008        Jarwar (Sindh)   873           33.7                              \[[@R28]\]
  Alam *et al.*         2008        Mianwali         697           1.9                               \[[@R29]\]
                        **Total**                    **178,322**   **4.7 (95% CI: 4.6 -4.8) 6.3)**   

Blood Donors {#s4}
============

Blood donor data constituted the largest data set. There were 27 studies and 3 unpublished data sets in this group. The total population covered in this group was 982,481 over the period 1996-2008 ([Table 3](#s4tbl3){ref-type="table"}). The studies covered all provinces of Pakistan. The serofrequency of HCV ranged from 0.3% in Multan \[[@R31]\] to 12.5% in Islamabad \[[@R32]\]. The mean frequency was 3.0% (95% CI: 3.0- 3.1). Only five studies \[[@R29]\]\[[@R32]\]\[[@R33]\]\[[@R34]\]\[[@R35]\] showed a frequency of \> 5%.

###### Sero-prevalence of HCV in Blood Donors

  **Author**          **Year**    **Place**    **Number**    **Anti HCV (%)**              **Reference**
  ------------------- ----------- ------------ ------------- ----------------------------- ---------------
  Kakepoto *et al.*   1996        Karachi      16,705        1.2                           \[[@R103]\]
  Bhatti *et al.*     1996        Rawalpindi   760           4.8                           \[[@R104]\]
  Lone *et al.*       1999        Lahore       186           4.3                           \[[@R105]\]
  Mujeeb              2000        Karachi      612           0.5                           \[[@R106]\]
  Tanwani and Ahmad   2000        Islamabad    1,345         12.5                          \[[@R32]\]
  DBTU                2001 UP     Rawalpindi   20,500        5.0                           \[[@R99]\]
  PBTS                2001 UP     Lahore       120,000       2.3                           \[[@R99]\]
  Adridi              2001 UP     Peshawar     19,000        4.0                           \[[@R99]\]
  Ryas *et al.*       2001        Rawalpindi   1,885         4.7                           \[[@R107]\]
  Ahmed *et al.*      2001        Karachi      1,410         4.4                           \[[@R108]\]
  Ahmad *et al.*      2002        Lahore       5,789         4.9                           \[[@R109]\]
  Khattak *et al.*    2002        Rawalpindi   103,858       4.0                           \[[@R110]\]
  Fayyaz *et al.*     2002        Bahawalpur   345           5.6                           \[[@R33]\]
  Mumtaz *et al.*     2002        Rawalpindi   553           6.2                           \[[@R34]\]
  Rahman *et al.*     2002        Lahore       166,183       4.4                           \[[@R111]\]
  Ali *et al.*        2003        Quetta       1635          1.8                           \[[@R112]\]
  Akhtar *et al.*     2004        Karachi      351,309       1.8                           \[[@R113]\]
  Ahmad *et al.*      2004        Peshawar     4,000         2.2                           \[[@R114]\]
  Mahmood *et al.*    2004        Multan       6,000         0.3                           \[[@R31]\]
  Sirhindi            2006        Lahore       18,216        4.2                           \[[@R115]\]
  Aziz                2006        Skardu       850           1.1                           \[[@R116]\]
  Khan                2006        Bahawalpur   27,938        2.5                           \[[@R117]\]
  Ujjan *et al.*      2006        Hyderabad    3,677         6.7                           \[[@R35]\]
  Mujeeb *et al.*     2006        Karachi      7,325         3.6                           \[[@R118]\]
  Chaudhary           2007        Rawalpindi   1,428         2.5                           \[[@R119]\]
  Alam and Naeem      2007        Gilgit       8.949         1.3                           \[[@R120]\]
  Ishaq *et al.*      2007        Thatta       310           1.3                           \[[@R121]\]
  Bhatti *et al.*     2007        Karachi      94,177        4.2                           \[[@R122]\]
  Khattak *et al.*    2008        Peshawar     1,131         4.1                           \[[@R123]\]
  Mujeeb and Pearce   2008        Karachi      5,345         7.5                           \[[@R124]\]
                      **Total**                **982,481**   **3.03 (95% CI: 3.0- 3.1)**   

Patients with Liver Diseases {#s5}
============================

Forty-one studies \[[@R36]\]\[[@R37]\]\[[@R38]\]\[[@R39]\]\[[@R40]\]\[[@R41]\]\[[@R42]\]\[[@R43]\]\[[@R44]\]\[[@R45]\]\[[@R46]\]\[[@R47]\]\[[@R48]\]\[[@R49]\]\[[@R50]\]\[[@R51]\]\[[@R52]\]\[[@R53]\]\[[@R54]\]\[[@R55]\]\[[@R56]\]\[[@R57]\]\[[@R58]\]\[[@R59]\]\[[@R60]\]\[[@R61]\]\[[@R62]\]\[[@R63]\]\[[@R64]\]\[[@R65]\]\[[@R66]\]\[[@R67]\]\[[@R68]\] dealing with the frequency of hepatitis C among patients with liver diseases were found, covering 7,765 patients over a period of 27 years from 1992 to 2008 ([Table 4](#s5tbl4){ref-type="table"},[Table 5](#s5tbl5){ref-type="table"}). Liver diseases included cirrhosis, chronic liver disease, chronic active hepatitis and hepatocellular carcinoma.

Fourteen studies \[[@R37]\]\[[@R38]\]\[[@R39]\]\[[@R40]\]\[[@R41]\]\[[@R42]\]\[[@R43]\]\[[@R44]\]\[[@R45]\]\[[@R46]\]\[[@R47]\]\[[@R48]\]\[[@R49]\]\[[@R50]\] pertained to cirrhosis patients. The number of individuals included in these studies was 1,902. HCV serofrequency in these individuals ranged from 10.5-79.6%, with an overall prevalence of 44.9% (95% CI = 42.6 - 47.2). Eleven studies \[[@R39]\]\[[@R51]\]\[[@R52]\]\[[@R53]\]\[[@R54]\]\[[@R55]\]\[[@R56]\]\[[@R57]\]\[[@R58]\]\[[@R59]\]\[[@R69]\] covering 3,144 patients with chronic liver disease showed a range of 13.3% to 86.0% HCV serofrequency. The mean frequency was 52.9% (95% CI: 51.1-54.7).

In 10 studies \[[@R36]\]\[[@R39]\]\[[@R40]\]\[[@R42]\]\[[@R60]\]\[[@R61]\]\[[@R62]\]\[[@R63]\]\[[@R64]\]\[[@R65]\] The HCV serofrequency in 739 cases of hepatocellular carcinoma was investigated ([Table 5](#s5tbl5){ref-type="table"}), and it ranged from 24% to 67.9%. The mean frequency in this subgroup was 50.6% (95% CI : 46.9-54.3). One thousand nine hundred and eighty patients with acute/chronic hepatitis from 6 studies had 58.2% (95% CI : 55.7- 60.4) HCV serofrequency \[[@R46]\]\[[@R51]\]\[[@R57]\]\[[@R66]\]\[[@R67]\]\[[@R68]\].

###### Sero-Prevalence of HCV in Liver Disease

  **Author**                  **Year**    **Place**        **Number**   **Anti HCV (%)**                   **Reference**
  --------------------------- ----------- ---------------- ------------ ---------------------------------- ---------------
  **Cirrhosis**                                                                                            
  Malik                       1992        Northern Areas   24           13.3                               \[[@R38]\]
  Malik                       1995        Rawalpindi       220          48.0                               \[[@R39]\]
  Makki                       1995        Karachi          67           10.5                               \[[@R40]\]
  Hussain                     1998        Lahore           50           52.0                               \[[@R14]\]
  Farooqi and Farooqi         1998        Peshawar         410          43.9                               \[[@R42]\]
  Umar *et al.*               1999        Rawalpindi       120          58.0                               \[[@R43]\]
  Mahmood *et al.*            1999        Karachi          202          37.7                               \[[@R44]\]
  Liaqat                      2000        Karachi          250          43.0                               \[[@R45]\]
  Shah *et al.*               2002        Islamabad        108          79.6                               \[[@R46]\]
  Iqbal                       2002        Peshawar         100          41.0                               \[[@R47]\]
  Khan                        2002        Lahore           94           68.0                               \[[@R56]\]
  Farooqi and Kahan           2002        Swat             55           59.0                               \[[@R49]\]
  Khurram                     2003        Rawalpindi       142          34.1                               \[[@R50]\]
  Mashud *et al.*             2004        DI Khan          60           13.3                               \[[@R125]\]
                              **Total**                    **1902**     **44.9 (95% CI = 42.6 - 47.2)**    
  **Chronic Liver Disease**                                                                                
  Malik                       1995        Rawalpindi       45           13.3                               \[[@R39]\]
  Tong *et al.*               1996        Rawalpindi       105          22.0                               \[[@R52]\]
  Sultana *et al.*            2000        Islamabad        108          29.6                               \[[@R53]\]
  Younas *et al.*             2001        Lahore           100          65.0                               \[[@R94]\]
  Tahir *et al.*              2001        Lahore           104          43.3                               \[[@R55]\]
  Khan *et al.*               2001        Islamabad        323          28.7                               \[[@R56]\]
  Khokhar                     2002        Islamabad        354          86.0                               \[[@R51]\]
  Khan                        2003        Hazara           614          40.8                               \[[@R57]\]
  Shaikh                      2003        Larkana          1,074        51.0                               \[[@R69]\]
  Bakhtiari *et al.*          2003        Rawalpindi       97           68.1                               \[[@R58]\]
  Wazir *et al.*              2003        Hyderabad        510          59.0                               \[[@R59]\]
                              **Total**                    **3144**     **52.9 ( 95% CI : 51.1 - 54.7)**   

###### Sero-Prevalence of HCV in Hepato-cellular Carcinoma and Acute/Chronic Hepatitis

  **Author**                      **Year**    **Place**    **Number**   **Anti HCV (%)**                 **Reference**
  ------------------------------- ----------- ------------ ------------ -------------------------------- ---------------
  **Hepato cellular Carcinoma**                                                                          
  Makki                           1991        Karachi      25           24.0                             \[[@R40]\]
  Malik                           1995        Rawalpindi   64           25.0                             \[[@R39]\]
  Mujeeb *et al.*                 1997        Karachi      54           33.0                             \[[@R60]\]
  Farooqi and Farooqi             2000        Peshawar     56           67.9                             \[[@R42]\]
  Mumtaz *et al.*                 2001        Rawalpindi   44           54.0                             \[[@R61]\]
  Khokhar *et al.*                2003        Islamabad    67           67.0                             \[[@R72]\]
  Siddiqui                        2005        Karachi      100          43.0                             \[[@R36]\]
  Bilal                           2006        Faisalabad   100          66.4                             \[[@R45]\]
  Almani *et al.*                 2008        Hyderabad    100          52.0                             \[[@R64]\]
  Abbas *et al.*                  2008        Karachi      129          51.2                             \[[@R65]\]
                                  **Total**                **739**      **50.6 (95% CI =46.9 - 54.3)**   
  **Acute /Chronic Hepatitis**                                                                           
  Haider *et al.*                 1994        Lahore       94           6.4                              \[[@R79]\]
  Umer                            1999        Rawalpindi   710          70.0                             \[[@R67]\]
  Almani *et al.*                 2002        Jamshoro     100          9.0                              \[[@R112]\]
  Khokhar                         2002        Islamabad    354          86.0                             \[[@R51]\]
  Shah *et al.*                   2002        Islamabad    108          79.6                             \[[@R115]\]
  Khan *et al.*                   2003        Abbotabad    614          40.8                             \[[@R57]\]
                                  **Total**                **1980**     **58.2 (95% CI =55.9 - 60.4)**   

Patients with Diseases Other than Hepatic Diseases {#s6}
==================================================

Sixteen studies focused on HCV serofrequency in patients with various diseases other than liver diseases ([Table 6](#s6tbl6){ref-type="table"}) \[[@R10]\]\[[@R70]\]\[[@R71]\]\[[@R72]\]\[[@R73]\]\[[@R74]\]\[[@R75]\]\[[@R76]\]\[[@R77]\]\[[@R78]\]\[[@R79]\]\[[@R80]\]\[[@R81]\]\[[@R82]\]\[[@R83]\]\[[@R84]\]\[[@R85]\]. These studies spanned a period of 8 years, from 1999 to 2006, and covered major cities. The mean frequency of HCV infection in patients with various medical diseases was 20.4% (95% CI : 18.4-22.5), 38% in haematological diseases (95% CI : 33.6-42.5), 7.9% among surgical diseases (95% CI : 6.9 - 9.0), and 1.3% in dental diseases.

###### Seroprevalence among patients of diseases other than Liver Disease.

  **Author**                    **Year**   **Place**                **Disease**                **Number**   **Anti HCV (%)**              **Reference**
  ----------------------------- ---------- ------------------------ -------------------------- ------------ ----------------------------- -------------------------------
  Khan                          2004       Mardan                   General                    700          9.0                           \[[@R10]\]
  Mumtaz andAftab               2005       Rawalpindi               General                    264          28.6                          \[[@R70]\]
  Gul and Iqbal                 2003       Lahore                   Renal Failure              50           68.0                          \[[@R71]\]
  Khokar *et al.*               2005       Islamabad                Renal Failure              97           23.7                          \[[@R72]\]
  Qazi *et al.*                 2004       Bahawalpur               Diabetes 2                 250          27.6                          \[[@R73]\]
  Bilwani *et al.*              2004       Karachi                  Lymphoprolifrative         143          29.2                          \[[@R89]\]
                                           **Total**                                                        **1504**                      **20.4 (95% CI = 18.4-22.5)**
  **Haematological Diseases**                                                                                                             
  Moatter *et al.*              1999       Karachi                  β -Thalassemia             100          35.0                          \[[@R106]\]
  Muhammad J                    2003       Peshawar (Thalassemia)   β -Thalassemia             80           36.2                          \[[@R126]\]
  Younus *et al.*               2004       Islamabad                β -Thalassemia             75           42.0                          \[[@R94]\]
  Burki *et al.*                2005       Islamabad                β -Thalassemia             180          41.7                          \[[@R74]\]
  Hussain                       2001       Peshawar                 Haemophillia               40           25.0                          \[[@R14]\]
                                           **Total**                                           **475**      **38 (95% CI = 33.6-42.5)**   
  **Psychological Diseases**                                                                                                              
  Shah and Dar                  2004       Islamabad                Depression                 135          22.9                          \[[@R80]\]
  Surgical Diseases                                                                                                                       
  Hussain and Fatima            2005       Karachi                  Surgical Diseases          750          16.2                          \[[@R81]\]
  Talpur *et al.*               2006       Nawabshah                Surgical Diseases          180          11.9                          \[[@R82]\]
  Khan *et al.*                 2007       Abbottabad               Orthopaedic Diseases       1630         3.1                           \[[@R83]\]
  Daudpota and Soomro           2008       Jacobabad                Surgical Diseases          150          14.0                          \[[@R84]\]
                                           **Total**                                           **2710**     **7.9 (95% CI = 6.9-9.0)**    
  **Dental Diseases**                                                                                                                     
  Khitab *et al.*               2005       Peshawar                 Dental Diseases Diseases   1,498        1.3                           \[[@R85]\]

Pregnant Women {#s7}
==============

Eleven studies \[[@R86]\]\[[@R87]\]\[[@R88]\]\[[@R89]\]\[[@R90]\]\[[@R91]\]\[[@R92]\]\[[@R93]\]\[[@R94]\]\[[@R95]\]\[[@R96]\] dealing with the serofrequency of HCV among pregnant women were found ([Table 7](#s7tbl7){ref-type="table"}). These studies spanned a period of 13 years from 1996 to 2008 and covered 6,148 women. The frequency in this group ranged from 3.3% to 29.1%. Overall serofrequency in this group was 7.3% (95% CI = 6.7 - 8.0).

###### Seroprevalence among Pregnant women

  **Author**           **Year**    **Place**   **Number**   **Anti HCV (%)**               **Reference**
  -------------------- ----------- ----------- ------------ ------------------------------ ---------------
  Khan                 1996        Lahore      417          9.3                            \[[@R56]\]
  Parker               1999        Lahore      417          4.0                            \[[@R90]\]
  Zafar *et al.*       2001        Lahore      300          6.0                            \[[@R88]\]
  Bilal                2002        Peshawar    352          5.1                            \[[@R74]\]
  Rizvi                2002        Karachi     120          6.6                            \[[@R80]\]
  Fayyaz               2004        Lahore      100          7.0                            \[[@R91]\]
  Khokar *et al.*      2004        Islamabad   503          4.8                            \[[@R92]\]
  Jaffery              2005        Islamabad   947          3.3                            \[[@R93]\]
  Yousafani *et al.*   2006        Hyderabad   103          29.1                           \[[@R94]\]
  Hakeem *et al.*      2006        RY Khan     450          18.2                           \[[@R41]\]
  Batool *et al.*      2008        Lahore      2,439        7.3                            \[[@R99]\]
                       **Total**               **6,148**    **7.3 (95% CI = 6.7 - 8.0)**   

Children {#s8}
========

Data from four studies \[[@R18]\]\[[@R86]\]\[[@R97]\]\[[@R98]\] covering 4,472 healthy children were analyzed ([Table 8](#s8tbl8){ref-type="table"}). HCV serofrequency among children ranged from 0.4% to 36.25%. The mean frequency was 1.8% (95% CI = 4.6 - 7.5). One study from Lahore in 1996 reported a 4.1% perinatal transmission of HCV in children of HCV- positive mothers. The serofrequency of HCV in thalassemics, and hemophiliacs was 35-42% \[[@R75]\]\[[@R76]\]\[[@R77]\]\[[@R78]\] and 25% \[[@R79]\], respectively.

###### Seroprevalence among Healthy Children

  **Author**       **Year**    **Place**   **Number**   **Anti HCV (%)**               **Reference**
  ---------------- ----------- ----------- ------------ ------------------------------ ---------------
  Jafri *et al.*   2006        Karachi     3,533        1.6                            \[[@R18]\]
  Akram            1995        Karachi     230          0.40                           \[[@R97]\]
  Khan             1996        Lahore      538          4.09                           \[[@R86]\]
  Hyder            2001        Lahore      171          0.58                           \[[@R98]\]
                   **Total**               **4472**     **1.8 (95% CI = 1.4 - 2.3)**   

Discussion {#s9}
==========

Many researchers have tried to derive a national or regional figure for HCV serofrequency based on the available data \[[@R99]\]\[[@R100]\]\[[@R101]\]. In 2005, Umar M and Khaar HTB \[[@R99]\], from Rawalpindi, collected data from various studies and reported a 9.8% frequency in 79,192 individuals. In 2006, Hafeez \[[@R99]\], from Islamabad, collected data from 98 studies and produced an estimate of 5.3%. Raja and Janjua \[[@R101]\], from Essex (UK), analyzed studies available on Medline from 1970 to 2005, and observed that the prevalence of HCV infection ranges from 0.4% in children, to 1.2% in healthy blood donors. Ali et al. reviewed data from 139 studies from 1994 to 2007 and concluded that the weighted average for hepatitis C antibody positivity was 3.0% (range 0.3-31.9%). Rates in the high-risk subgroups were far higher \[[@R100]\].

The data analyzed in this article shows HCV positivity (95% CI: 4.6 - 4.8) among 178,322 healthy individuals and 3.03% positivity (95% CI: 3.00 - 3.06) among 982,481 healthy blood donors. This figure is significantly lower (P \< 0.0001) than the figure of 9.8% quoted by Umar M and Khaar HTB \[[@R99]\]. However, our estimates are significantly higher (P \< 0.00001) than the 3% figure quoted by Ali et al. \[[@R100]\] for healthy individuals. Our estimates are closer to the figure of 5.3% given by Hafeez \[[@R99]\]. According to several studies, HCV genotype 3 is the most frequent genotype found in Pakistan ([Table 9](#s9tbl9){ref-type="table"}).

Most of the available Pakistani data on HCV pertains to blood donors, probably because for reasons of convenience and access to a large sample size, and may not truly represent the general population \[[@R100]\]. If high-risk blood donors are screened out (those with jaundice, injection drug users etc), the frequency in the general population may be underestimated. If professional blood donors (who are often injection-drug users who sell their blood to make money) are included, the figures may be overestimated.

The number of subjects studied, other than healthy blood donors, appears very small, and also there is a lack of representation from across the country \[[@R101]\]. The frequency of HCV positivity in Pakistan is significantly higher (P \< 0.0001) when compared to the corresponding populations in the surrounding countries ([Table 10](#s9tbl10){ref-type="table"}).

We noted a highly variable serofrequency in different studies of similar populations, even within the same province. One of the reasons for such variability in the results has been explained by Ali et al. \[[@R100]\]. The authors observed that unlike highly contagious diseases like measles that have a more predictable seroprevalence, blood-borne illnesses like hepatitis and HIV are transmitted sporadically or in microepidemics. According to them these microepidemics may account for wide variations in prevalence within a nation, a province, or even a community, and methodological differences in sampling strategies may also contribute to differences in seroprevalence within similar regions or populations \[[@R100]\].

According to the \"Burden of Disease Study\" carried out by Hyder and Morrow in 2001, chronic liver diseases are the 5th commonest cause of premature mortality in Pakistan and the 11th commonest cause of disabilities \[[@R102]\]. Although between 75-85% of infections move on to chronic hepatitis C, the progress may be slow. Hence most people who are infected do not experience symptoms and are unaware of their infection. They are not able to benefit from available treatment that may clear them of the virus. They may also unknowingly spread the virus to others. Currently, there is no vaccine to prevent HCV infection. Effective but costly treatment is available. The high frequency and its contribution to premature mortality and disability call for massive awareness campaigns to combat the menace of this infectious disease.

###### Frequency of Genotypes[a](#Fs9tbl9a){ref-type="table-fn"}

  **Author**   **Year**    **Place**    **Number (Typable)**   **Genotype (%)**   **Reference**                                                 
  ------------ ----------- ------------ ---------------------- ------------------ --------------- --------- --------- --------- --------- ----- -------------
  Azhar        2003        Bahawalpur   105                    6.0                4.8             69.6      2.4       \-        0.8       \-    \[[@R122]\]
  Ansari       2002        Karachi      255                    12.0               2.3             77.6      2.3       0.4       2.7       2.3   \[[@R127]\]
  Khokhar      2002        Islamabad    148                    \-                 \-              64.1      \-        \-        \-        \-    \[[@R125]\]
  Zuberi       2002        Karachi      215                    8.4                \-              79.5      \-        \-        \-        8.8   \[[@R88]\]
  Nasir        2001        Rawalpindi   39                     5.1                2.6             59.9      5.2       12.8      15.4      \-    \[[@R128]\]
  Mumtaz       2005        Karachi      725                    7.9                1.2             87.8      5.0       \-        0.8       \-    \[[@R129]\]
               **Total**   **725**      **7.7**                **1.6**            **80.5**        **3.1**   **0.9**   **1.3**   **1.7**         

^a^ Due to missing data in some studies, percentages do not add to 100

###### Comparison of HCV Frequency with surrounding countries

  **Country**   **Year**   **Population**   **Number**   **Prevalence (%)**   **Reference**
  ------------- ---------- ---------------- ------------ -------------------- ---------------
  Myanmar       2006       Healthy Adults   362          2.5                  \[[@R130]\]
  India         2003       Blood Donors     28,956       0.66                 \[[@R126]\]
  Nepal         2004       Healthy Adults   103          1.0                  \[[@R131]\]
  Iran          2006       Healthy Adults   1721         1.0                  \[[@R132]\]
  Afghanistan   2006       Healthy Women    4452         0.31                 \[[@R133]\]
  Pakistan      2009       Healthy Adults   178,322      4.7                  This review

Conclusions {#s10}
===========

The frequency of hepatitis C infection in Pakistan is high (4.7%), varying from 0.4% - 33.7%, indicating pockets of infections. The frequency is significantly higher than in surrounding countries. The contribution of this high frequency to premature mortality and disability calls for massive awareness campaigns.
